Content about Chemistry

December 23, 2013

A federal court decision paves the way for Amneal Pharmaceuticals and its South Korean partnering company to market a drug for treating gastroesophageal reflux disease, the companies said Monday.

BRIDGEWATER, N.J. — A federal court decision paves the way for Amneal Pharmaceuticals and its South Korean partnering company to market a drug for treating gastroesophageal reflux disease, the companies said Monday.

December 23, 2013

The Food and Drug Administration has approved a new drug made by United Therapeutics for treating pulmonary arterial hypertension, the company said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by United Therapeutics for treating pulmonary arterial hypertension, the company said Monday.

The FDA approved Orenitram (treprostinil) extended-release tablets for treating certain PAH patients to improve exercise capacity. PAH is a disease in which abnormally high blood pressure in the arteries of the lungs causes the right side of the heart to work harder than normal, according to the National Library of Medicine.

December 18, 2013

Blue Diamond Growers, an almond processing and marketing company, announced the results of a recent national survey by Harris Interactive which provided a closer look at Americans' New Year's resolutions.

SACRAMENTO, Calif. — Blue Diamond Growers, an almond processing and marketing company, announced the results of a recent national survey by Harris Interactive which provided a closer look at Americans' New Year's resolutions.

Nearly 75% of Americans will focus on healthier eating and improving fitness, according to the survey. The results also revealed that almost a quarter of Americans will ultimately fail to keep those resolutions for more than three months.

December 18, 2013

Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

BALTIMORE — Lupin has launched a generic drug for treating HIV, following its victory in a patent-infringement suit in federal court, the Indian drug maker said Wednesday.

Lupin's U.S. subsidiary launched its generic version of ViiV Healthcare's Trizivir (abacavir sulfate; lamivudine; zidovudine) tablets in the 300-mg/150-mg/300-mg strength. The launch follows a ruling by the U.S. District Court for the District of Delaware that the drug did not infringe on Viiv's patent.

December 18, 2013

A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

NEW YORK — A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

December 17, 2013

Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.

Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.

December 17, 2013

Greenstone has launched a version of a drug used to treat fungal infections, the company said.

PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.

Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.

Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.

 

December 16, 2013

The Food and Drug Administration may require makers of antibacterial soaps to perform clinical trials to show their products are better at preventing infections and disease than ordinary soaps.

SILVER SPRING, Md. — The Food and Drug Administration may require makers of antibacterial soaps to perform clinical trials to show their products are better at preventing infections and disease than ordinary soaps, part of a larger effort by the agency to ensure the safety and efficacy of antibacterial products and slow down the rise of antibiotic-resistant bacteria.

December 12, 2013

Kaz announced the launch of the Braun Forehead Thermometer, which features a lightweight, ergonomic design, providing a step-by-step on-product usage guide and user-facing digital temperature readouts on a large, backlit screen.

SOUTHBOROUGH, Mass. — Kaz on Thursday announced the launch of the Braun Forehead Thermometer, which features a lightweight, ergonomic design, providing a step-by-step on-product usage guide and user-facing digital temperature readouts on a large, backlit screen. 

In addition, the thermometer's fever guidance system indicates the severity of each reading with a green, yellow or red light, helping parents easily decipher and monitor the status of their child's temperature. 

December 11, 2013

The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said.

SILVER SPRING, Md. – The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said Wednesday.

The FDA announced the approval of generic duloxetine delayed-release capsules manufactured by Aurobindo Pharma, Dr. Reddy's Labs, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries and Torrent Pharmaceuticals.

December 11, 2013

An Albertsons store in Billings, Mont., is home to a retail clinic staffed by physician assistants and nurse practitioners who will treat patients for allergies, infections, bug bites, pain and other minor health problems, according to published reports.

NEW YORK — An Albertsons store in Billings, Mont., is home to a retail clinic staffed by physician assistants and nurse practitioners who will treat patients for allergies, infections, bug bites, pain and other minor health problems, according to published reports.

The Billings Gazette reported that Billings Clinic opened at Albertsons its first retail clinic, called ExpressCare. Additional clinics are planned for spring and summer next year. The clinic is staffed by nurse practitioners and physician assistants.

December 11, 2013

According to new research commissioned by Nelson, of the most commonly recommended vitamins and minerals, patients have the hardest time tolerating iron.

NORTH ANDOVER, Mass. — According to new research commissioned by Nelson, of the most commonly recommended vitamins and minerals, patients have the hardest time tolerating iron. 

Researchers from Market Dynamics surveyed 300 U.S. healthcare professionals including physicians, pharmacists, nurse practitioners and dieticians/nutritionists to learn more about their patient conversations around vitamin and mineral supplements. Among the findings — iron led the way in patient complaints. 

December 5, 2013

Church & Dwight announced plans to expand its gummy vitamin production capacity through the addition of a new production line to be constructed at its manufacturing facility in Pennsylvania.

EWING, N.J. — Church & Dwight on Thursday announced plans to expand its gummy vitamin production capacity through the addition of a new production line to be constructed at its manufacturing facility in Pennsylvania. The company will continue to manufacture gummy vitamins at its two facilities in Washington. 

Construction will begin in January 2014 and the line is scheduled to be operational in the first quarter of 2015.

December 5, 2013

Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

 

December 4, 2013

The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.

BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.

Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012's $13.4 billion.

December 3, 2013

Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

NEW YORK — Forest Labs is spending at least $240 million to buy rights to a psychiatric drug made by Merck, the New York-based drug maker said.

Forest said it would buy the U.S. rights for Merck's Saphris (asenapine), a tablet dissolved under the tongue for the treatment of schizophrenia and manic episodes in patients with bipolar disorder. Forest will pay Merck $240 million upfront, as well as milestone payments based on sales, while Merck will supply the drug. Forest will market the drug and conduct clinical studies.

December 3, 2013

Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

HAYWARD, Calif. — Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

December 3, 2013

Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

NEWARK, N.J. — Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.

Developed alongside pharmacist, Robert Graci, Inergetics has created a unique formula to support healthy nerve function and specifically help diabetic patients who experience nerve-related symptoms in their extremities, which include tingling, pain, burning and loss of sensation, the company stated. 

December 3, 2013

The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to a generic drug used to treat prostate disease, agency records showed.

The FDA granted tentative approval to Roxane Labs' dutasteride capsules in the 0.5-mg strength. The drug is a generic version of GSK's Avodart, used to treat benign prostatic hyperplasia.

Tentative approval means that a drug meets the agency's conditions for approval, but can't receive final approval until Avodart loses its patent protection, which will occur in 2015.

 

December 2, 2013

Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.

MALVERN, Pa. — Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.

The deal centers on the development and potential commercialization of experimental drugs containing the opioid painkiller hydrocodone.

December 2, 2013

The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca's Seroquel.

Various versions of the drug have annual sales of about $59 million, according to IMS Health.

 

December 2, 2013

The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

JERUSALEM — The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

Teva said the drug, Treanda (bendamustine hydrochloride), received the designation for indolent B-cell non-Hodgkins lymphoma through October 2015 that has progressed during or within six months of treatment with a regimen containing Rituxan (rituximab), marketed by Genentech and Biogen Idec. The FDA gives orphan drug designation to treatments for diseases affecting fewer than 200,000 people in the United States.

December 2, 2013

Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

NEW YORK — Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

November 27, 2013

Researchers at the University of Dundee and University College London on Wednesday reported that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake, and potentially become an added risk factor for heart disease.

LONDON — Researchers at the University of Dundee and University College London on Wednesday found that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake and potentially become an added risk factor for heart disease.

They say the public "should be warned about the potential dangers of high sodium intake from prescribed medicines" and that sodium-containing formulations "should be prescribed with caution only if the perceived benefits outweigh the risks."

November 27, 2013

Treatment of influenza with antiviral medicines like Tamiflu and Relenza may improve survival rates in children, according to a study published Nov. 25 in Pediatrics.

ELK GROVE VILLAGE, Ill. — Treatment of influenza with such antiviral medicines as Tamiflu and Relenza may improve survival rates in children, according to a study published on Nov. 25 in Pediatrics

Researchers from the California Department of Public Health analyzed data abstracted from medical records to characterize the outcomes of pediatric patients hospitalized with the flu between April 3, 2009 and September 30, 2012.